The renin-angiotensin-aldosterone system and its therapeutic targets

Experimental Eye Research

Volumn 186, Issue , 2019, Pages

  Mirabito Colafella, Katrina M ^a   Bovée, Dominique M ^b   Danser, A H Jan ^b  

^a MONASH UNIVERSITY   (Australia)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE2; Angiotensin converting enzyme inhibitor; Angiotensinogen siRNA; AT1 receptor blocker; AT2 receptor agonist; Mas receptor agonist; Mineralocorticoid receptor antagonist; Neprilysin inhibitor; Renin inhibitor

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; RENIN INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; OLIGOPEPTIDE; RENIN INHIBITORY PEPTIDE; SMALL INTERFERING RNA;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HUMAN; KIDNEY DISEASE; PRECURSOR; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; BODY FLUID; DRUG EFFECT; GENETICS; HOMEOSTASIS; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; BLOOD PRESSURE; BODY FLUIDS; ENZYME INHIBITORS; HOMEOSTASIS; HUMANS; NEPRILYSIN; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; RNA, SMALL INTERFERING;

EID: 85069602714     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2019.05.020     Document Type: Review

References (102)

1. Balcarek, J., Seva Pessoa, B., Bryson, C., Azizi, M., Menard, J., Garrelds, I.M., McGeehan, G., Reeves, R.A., Griffith, S.G., Danser, A.H., Gregg, R., Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 63 (2014), 942–950.
2. Basu, R., Poglitsch, M., Yogasundaram, H., Thomas, J., Rowe, B.H., Oudit, G.Y., Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J. Am. Coll. Cardiol. 69 (2017), 805–819.
3. Batenburg, W.W., Garrelds, I.M., Bernasconi, C.C., Juillerat-Jeanneret, L., van Kats, J.P., Saxena, P.R., Danser, A.H., Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109 (2004), 2296–2301.
4. Batenburg, W.W., Verma, A., Wang, Y., Zhu, P., van den Heuvel, M., van Veghel, R., Danser, A.H., Li, Q., Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy–a study in transgenic (mREN2)27 rats. PLoS One, 9, 2014, e100954.
5. Becker, L.K., Totou, N., Moura, S., Kangussu, L., Millan, R.D.S., Campagnole-Santos, M.J., Coelho, D., Motta-Santos, D., Santos, R.A.S., Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment. Int. J. Sports Med. 39 (2018), 743–748.
6. Bernardi, S., Michelli, A., Zuolo, G., Candido, R., Fabris, B., Update on RAAS modulation for the treatment of diabetic cardiovascular disease. J. Diabetes Res., 2016, 2016, 8917578.
7. Bomback, A.S., Klemmer, P.J., The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3 (2007), 486–492.
8. Bosnyak, S., Jones, E.S., Christopoulos, A., Aguilar, M.I., Thomas, W.G., Widdop, R.E., Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. (Lond.) 121 (2011), 297–303.
9. Bousquet, E., Beydoun, T., Rothschild, P.R., Bergin, C., Zhao, M., Batista, R., Brandely, M.L., Couraud, B., Farman, N., Gaudric, A., Chast, F., Behar-Cohen, F., Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35 (2015), 2505–2515.
10. Bramlage, P., Swift, S.L., Thoenes, M., Minguet, J., Ferrero, C., Schmieder, R.E., Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur. J. Heart Fail. 18 (2016), 28–37.
11. Brouwers, S., Smolders, I., Wainford, R.D., Dupont, A.G., Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats. Clin. Sci. (Lond.) 129 (2015), 81–92.
12. Campbell, D.J., Kladis, A., Duncan, A.M., Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 22 (1993), 513–522.
13. Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H.H., Bilous, R., Sjolie, A.K., Group, D.P.S., Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372 (2008), 1394–1402.
14. Chaturvedi, N., Sjolie, A.K., Stephenson, J.M., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Z., Fuller, J.H., Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of Lisinopril in insulin-dependent diabetes mellitus. Lancet 351 (1998), 28–31.
15. Choudhary, R., Kapoor, M.S., Singh, A., Bodakhe, S.H., Therapeutic targets of renin-angiotensin system in ocular disorders. J. Curr. Ophthalmol. 29 (2017), 7–16.
16. Colafella, K.M., Hilliard, L.M., Denton, K.M., Epochs in the depressor/pressor balance of the renin-angiotensin system. Clin. Sci. (Lond.) 130 (2016), 761–771.
17. Crooke, S.T., Witztum, J.L., Bennett, C.F., Baker, B.F., RNA-targeted therapeutics. Cell Metabol. 27 (2018), 714–739.
18. Danser, A.H., Local renin-angiotensin systems: the unanswered questions. Int. J. Biochem. Cell Biol. 35 (2003), 759–768.
19. Danser, A.H., Derkx, F.H., Admiraal, P.J., Deinum, J., de Jong, P.T., Schalekamp, M.A., Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. 35 (1994), 1008–1018.
20. Danser, A.H., van Kats, J.P., Admiraal, P.J., Derkx, F.H., Lamers, J.M., Verdouw, P.D., Saxena, P.R., Schalekamp, M.A., Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 24 (1994), 37–48.
21. Danser, A.H., van Kesteren, C.A., Bax, W.A., Tavenier, M., Derkx, F.H., Saxena, P.R., Schalekamp, M.A., Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 96 (1997), 220–226.
22. Danser, A.H.J., Deinum, J., Renin, prorenin and the putative (pro)renin receptor. Hypertension 46 (2005), 1069–1076.
23. Daruich, A., Matet, A., Dirani, A., Gallice, M., Nicholson, L., Sivaprasad, S., Behar-Cohen, F., Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol., 5, 2016, 2.
24. de Lannoy, L.M., Schuijt, M.P., Saxena, P.R., Schalekamp, M.A.D.H., Danser, A.H.J., Angiotensin-converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of isolated perfused rat heart. J. Hypertens. 19 (2001), 959–965.
25. Foureaux, G., Nogueira, B.S., Coutinho, D.C., Raizada, M.K., Nogueira, J.C., Ferreira, A.J., Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina. Braz. J. Med. Biol. Res. 48 (2015), 1109–1114.
26. Fraga-Silva, R.A., Savergnini, S.Q., Montecucco, F., Nencioni, A., Caffa, I., Soncini, D., Costa-Fraga, F.P., De Sousa, F.B., Sinisterra, R.D., Capettini, L.A., Lenglet, S., Galan, K., Pelli, G., Bertolotto, M., Pende, A., Spinella, G., Pane, B., Dallegri, F., Palombo, D., Mach, F., Stergiopulos, N., Santos, R.A., da Silva, R.F., Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb. Haemost. 111 (2014), 736–747.
27. Gao, J., Zucker, I.H., Gao, L., Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure. Am. J. Hypertens. 27 (2014), 1248–1256.
28. Gu, H., Xie, Z., Li, T., Zhang, S., Lai, C., Zhu, P., Wang, K., Han, L., Duan, Y., Zhao, Z., Yang, X., Xing, L., Zhang, P., Wang, Z., Li, R., Yu, J.J., Wang, X., Yang, P., Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci. Rep., 6, 2016, 19840.
29. Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., Krahenbuhl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52 (2013), 783–792.
30. Ito, S., Satoh, M., Tamaki, Y., Gotou, H., Charney, A., Okino, N., Akahori, M., Zhang, J., Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens. Res. 38 (2015), 269–275.
31. Jaisser, F., Farman, N., Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68 (2016), 49–75.
32. Kaschina, E., Namsolleck, P., Unger, T., AT2 receptors in cardiovascular and renal diseases. Pharmacol. Res. 125 (2017), 39–47.
33. Kemp, B.A., Howell, N.L., Keller, S.R., Gildea, J.J., Padia, S.H., Carey, R.M., AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension. Circ. Res. 119 (2016), 532–543.
34. Khan, A., Benthin, C., Zeno, B., Albertson, T.E., Boyd, J., Christie, J.D., Hall, R., Poirier, G., Ronco, J.J., Tidswell, M., Hardes, K., Powley, W.M., Wright, T.J., Siederer, S.K., Fairman, D.A., Lipson, D.A., Bayliffe, A.I., Lazaar, A.L., A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit. Care, 21, 2017, 234.
35. Klotz, S., Foronjy, R.F., Dickstein, M.L., Gu, A., Garrelds, I.M., Danser, A.H., Oz, M.C., D'Armiento, J., Burkhoff, D., Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 112 (2005), 364–374.
36. Koizumi, M., Niimura, F., Fukagawa, M., Matsusaka, T., Adipocytes do not significantly contribute to plasma angiotensinogen. J. Renin-Angiotensin-Aldosterone Syst. JRAAS, 17, 2016 1470320316672348.
37. Kolkhof, P., Borden, S.A., Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol. Cell. Endocrinol. 350 (2012), 310–317.
38. Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Barfacker, L., Eitner, F., Albrecht-Kupper, B., Schafer, S., Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64 (2014), 69–78.
39. Kostis, J.B., Packer, M., Black, H.R., Schmieder, R., Henry, D., Levy, E., Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17 (2004), 103–111.
40. Kurtz, A., Della Bruna, R., Pfeilschifter, J., Taugner, R., Bauer, C., Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 4769–4773.
41. Liu, Y.H., Yang, X.P., Sharov, V.G., Nass, O., Sabbah, H.N., Peterson, E., Carretero, O.A., Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J. Clin. Investig. 99 (1997), 1926–1935.
42. MacFadyen, R.J., Barr, C.S., Struthers, A.D., Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35 (1997), 30–34.
43. Marques, F.D., Melo, M.B., Souza, L.E., Irigoyen, M.C., Sinisterra, R.D., de Sousa, F.B., Savergnini, S.Q., Braga, V.B., Ferreira, A.J., Santos, R.A., Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int. J. Hypertens., 2012, 795452.
44. Matavelli, L.C., Siragy, H.M., AT2 receptor activities and pathophysiological implications. J. Cardiovasc. Pharmacol. 65 (2015), 226–232.
45. Matsusaka, T., Niimura, F., Shimizu, A., Pastan, I., Saito, A., Kobori, H., Nishiyama, A., Ichikawa, I., Liver angiotensinogen is the primary source of renal angiotensin II. J. Am. Soc. Nephrol. 23 (2012), 1181–1189.
46. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K., Zile, M.R., Investigators, P.-H., Committees, Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371 (2014), 993–1004.
47. Michel, F., Ambroisine, M.L., Duriez, M., Delcayre, C., Levy, B.I., Silvestre, J.S., Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109 (2004), 1933–1937.
48. Miller, A.G., Tan, G., Binger, K.J., Pickering, R.J., Thomas, M.C., Nagaraj, R.H., Cooper, M.E., Wilkinson-Berka, J.L., Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59 (2010), 3208–3215.
49. Mooser, V., Nussberger, J., Juillerat, L., Burnier, M., Waeber, B., Bidiville, J., Pauly, N., Brunner, H.R., Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 15 (1990), 276–282.
50. Moravski, C.J., Skinner, S.L., Stubbs, A.J., Sarlos, S., Kelly, D.J., Cooper, M.E., Gilbert, R.E., Wilkinson-Berka, J.L., The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. 162 (2003), 151–160.
51. Moreira de Macedo, S., Guimaraes, T.A., Feltenberger, J.D., Sousa Santos, S.H., The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 62 (2014), 189–196.
52. Mullick, A.E., Yeh, S.T., Graham, M.J., Engelhardt, J.A., Prakash, T.P., Crooke, R.M., Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension 70 (2017), 566–576.
53. Oudit, G.Y., Liu, G.C., Zhong, J., Basu, R., Chow, F.L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J.M., Herzenberg, A.M., Kassiri, Z., Scholey, J.W., Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59 (2010), 529–538.
54. Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Rouleau, J.L., Swedberg, K., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106 (2002), 920–926.
55. Patel, V.B., Zhong, J.C., Grant, M.B., Oudit, G.Y., Role of the ACE2/angiotensin 1-7 Axis of the renin-angiotensin system in heart failure. Circ. Res. 118 (2016), 1313–1326.
56. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., Gatlin, M., Eplerenone Post-Acute Myocardial Infarction Heart Failure, E., Survival Study, I., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003), 1309–1321.
57. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J., Wittes, J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999), 709–717.
58. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., Falk, V., Gonzalez-Juanatey, J.R., Harjola, V.P., Jankowska, E.A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J.T., Pieske, B., Riley, J.P., Rosano, G.M., Ruilope, L.M., Ruschitzka, F., Rutten, F.H., van der Meer, P., Authors/Task Force, M., Document, R., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18 (2016), 891–975.
59. Prasad, T., Roksnoer, L.C., Zhu, P., Verma, A., Li, Y., Batenburg, W.W., de Vries, R., Danser, A.H., Li, Q., Beneficial effects of combined AT1 receptor/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye. Invest. Ophthalmol. Vis. Sci. 57 (2016), 6722–6730.
60. Qiu, Y., Shil, P.K., Zhu, P., Yang, H., Verma, A., Lei, B., Li, Q., Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. Invest. Ophthalmol. Vis. Sci. 55 (2014), 3809–3818.
61. Rajagopalan, S., Duquaine, D., King, S., Pitt, B., Patel, P., Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 (2002), 2212–2216.
62. Ray, K.K., Landmesser, U., Leiter, L.A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R.P., Turner, T., Visseren, F.L., Wijngaard, P., Wright, R.S., Kastelein, J.J., Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376 (2017), 1430–1440.
63. Rentzsch, B., Todiras, M., Iliescu, R., Popova, E., Campos, L.A., Oliveira, M.L., Baltatu, O.C., Santos, R.A., Bader, M., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52 (2008), 967–973.
64. Rocha, R., Funder, J.W., The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci. 970 (2002), 89–100.
65. Rodrigues Prestes, T.R., Rocha, N.P., Miranda, A.S., Teixeira, A.L., Simoes, E.S.A.C., The anti-inflammatory potential of ACE2/angiotensin-(1-7)/mas receptor Axis: evidence from basic and clinical research. Curr. Drug Targets 18 (2017), 1301–1313.
66. Ruilope, L.M., Dukat, A., Bohm, M., Lacourciere, Y., Gong, J., Lefkowitz, M.P., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (2010), 1255–1266.
67. Santos, R.A., Angiotensin-(1-7). Hypertension 63 (2014), 1138–1147.
68. Santos, S.H., Giani, J.F., Burghi, V., Miquet, J.G., Qadri, F., Braga, J.F., Todiras, M., Kotnik, K., Alenina, N., Dominici, F.P., Santos, R.A., Bader, M., Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats. J. Mol. Med. (Berl.) 92 (2014), 255–265.
69. Saris, J.J., van den Eijnden, M.M.E.D., Lamers, J.M.J., Saxena, P.R., Schalekamp, M.A.D.H., Danser, A.H.J., Prorenin-induced myocyte proliferation. Hypertension 39 (2002), 573–577.
70. Schrier, R.W., Aldosterone 'escape' vs 'breakthrough'. Nat. Rev. Nephrol., 6, 2010, 61.
71. Sica, D.A., The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point. Curr. Hypertens. Rep. 12 (2010), 67–73.
72. Solomon, S.D., Rizkala, A.R., Gong, J., Wang, W., Anand, I.S., Ge, J., Lam, C.S.P., Maggioni, A.P., Martinez, F., Packer, M., Pfeffer, M.A., Pieske, B., Redfield, M.M., Rouleau, J.L., Van Veldhuisen, D.J., Zannad, F., Zile, M.R., Desai, A.S., Shi, V.C., Lefkowitz, M.P., McMurray, J.J.V., Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 5 (2017), 471–482.
73. Steckelings, U., Lindblad, L., Leisvuori, A., Lovro, Z., Vainio, P., Graens, J., Dahlof, B., Jansson, P., Unger, T., Wiksten, A., Korhonen, P., Scheinin, M., Successful completion of a phase I, randomized, double-blind, placebo controlled, single ascending dose trial for the first in class Angiotensin At2-receptor agonist compound 21. J. Hypertens. 35 (2017), e105–e106 [Pp.02.17].
74. Suzuki, G., Morita, H., Mishima, T., Sharov, V.G., Todor, A., Tanhehco, E.J., Rudolph, A.E., McMahon, E.G., Goldstein, S., Sabbah, H.N., Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 (2002), 2967–2972.
75. Tamargo, M., Tamargo, J., Future drug discovery in renin-angiotensin-aldosterone system intervention. Expert Opin. Drug Discov. 12 (2017), 827–848.
76. Tom, B., Garrelds, I.M., Scalbert, E., Stegmann, A.P., Boomsma, F., Saxena, P.R., Danser, A.H., ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 251–256.
77. Treml, B., Neu, N., Kleinsasser, A., Gritsch, C., Finsterwalder, T., Geiger, R., Schuster, M., Janzek, E., Loibner, H., Penninger, J., Loeckinger, A., Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit. Care Med. 38 (2010), 596–601.
78. Uijl, E., Mirabito Colafella, K.M., Ren, L., Sun, Y., van Veghel, R., Garrelds, I.M., de Vries, R., Poglitsch, M., Zlatev, I., Kim, J.B., Hoorn, E.J., Foster, D.J., Danser, A.H.J., Strong and sustained antihypertensive effect of small interfering RNA targeting liver angioteninsogen. Hypertension 73 (2019), 1249–1257.
79. van Esch, J.H., Moltzer, E., van Veghel, R., Garrelds, I.M., Leijten, F., Bouhuizen, A.M., Danser, A.H., Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J. Hypertens. 28 (2010), 2145–2155.
80. van Esch, J.H., Tom, B., Dive, V., Batenburg, W.W., Georgiadis, D., Yiotakis, A., van Gool, J.M., de Bruijn, R.J., de Vries, R., Danser, A.H., Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45 (2005), 120–125.
81. van Kats, J.P., Chai, W., Duncker, D.J., Schalekamp, M.A., Danser, A.H., Adrenal angiotensin: origin and site of generation. Am. J. Hypertens. 18 (2005), 1104–1110.
82. van Kats, J.P., Duncker, D.J., Haitsma, D.B., Schuijt, M.P., Niebuur, R., Stubenitsky, R., Boomsma, F., Schalekamp, M.A., Verdouw, P.D., Danser, A.H., Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102 (2000), 1556–1563.
83. van Kats, J.P., Schalekamp, M.A., Verdouw, P.D., Duncker, D.J., Danser, A.H., Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int. 60 (2001), 2311–2317.
84. Verdonk, K., Durik, M., Abd-Alla, N., Batenburg, W.W., van den Bogaerdt, A.J., van Veghel, R., Roks, A.J., Danser, A.H., van Esch, J.H., Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension 60 (2012), 722–729.
85. Verdonk, K., Saleh, L., Lankhorst, S., Smilde, J.E., van Ingen, M.M., Garrelds, I.M., Friesema, E.C., Russcher, H., van den Meiracker, A.H., Visser, W., Danser, A.H., Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension 65 (2015), 1316–1323.
86. Voors, A.A., Gori, M., Liu, L.C., Claggett, B., Zile, M.R., Pieske, B., McMurray, J.J., Packer, M., Shi, V., Lefkowitz, M.P., Solomon, S.D., Investigators, P., Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur. J. Heart Fail. 17 (2015), 510–517.
87. Wagner, J., Danser, A.H.J., Derkx, F.H., de Jong, T.V., Paul, M., Mullins, J.J., Schalekamp, M.A., Ganten, D., Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 80 (1996), 159–163.
88. Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A.K., Wu, X., Johansson, B., Holm, M., Botoros, M., Karlen, A., Pettersson, A., Nyberg, F., Fandriks, L., Gallo-Payet, N., Hallberg, A., Alterman, M., Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 47 (2004), 5995–6008.
89. Wang, B., Wang, F., Zhang, Y., Zhao, S.H., Zhao, W.J., Yan, S.L., Wang, Y.G., Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 3 (2015), 263–274.
90. Wang, Y., Del Borgo, M., Lee, H.W., Baraldi, D., Hirmiz, B., Gaspari, T.A., Denton, K.M., Aguilar, M.I., Samuel, C.S., Widdop, R.E., Anti-fibrotic potential of AT2 receptor agonists. Front. Pharmacol., 8, 2017, 564.
91. Wei, C.C., Meng, Q.C., Palmer, R., Hageman, G.R., Durand, J., Bradley, W.E., Farrell, D.M., Hankes, G.H., Oparil, S., Dell'Italia, L.J., Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99 (1999), 2583–2589.
92. Wilkinson-Berka, J.L., Tan, G., Binger, K.J., Sutton, L., McMaster, K., Deliyanti, D., Perera, G., Campbell, D.J., Miller, A.G., Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia 54 (2011), 2724–2735.
93. Wilkinson-Berka, J.L., Tan, G., Jaworski, K., Ninkovic, S., Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 20 (2007), 423–430.
94. Wong, P.C., Guo, J., Zhang, A., The renal and cardiovascular effects of natriuretic peptides. Adv. Physiol. Educ. 41 (2017), 179–185.
95. Wysocki, J., Ye, M., Rodriguez, E., Gonzalez-Pacheco, F.R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K.B., Ferrario, C.M., Penninger, J.M., Batlle, D., Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55 (2010), 90–98.
96. Ye, F., Wang, Y., Wu, C., Howatt, D.A., Wu, C.H., Balakrishnan, A., Mullick, A.E., Graham, M.J., Danser, A.H.J., Wang, J., Daugherty, A., Lu, H.S., Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report. Arterioscler. Thromb. Vasc. Biol. 39 (2019), 150–155.
97. Ye, M., Wysocki, J., William, J., Soler, M.J., Cokic, I., Batlle, D., Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17 (2006), 3067–3075.
98. Zhang, S.X., Ma, J.X., Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin. Eye Res. 26 (2007), 1–37.
99. Zhao, M., Celerier, I., Bousquet, E., Jeanny, J.C., Jonet, L., Savoldelli, M., Offret, O., Curan, A., Farman, N., Jaisser, F., Behar-Cohen, F., Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Investig. 122 (2012), 2672–2679.
100. Zhao, M., Mantel, I., Gelize, E., Li, X., Xie, X., Arboleda, A., Seminel, M., Levy-Boukris, R., Dernigoghossian, M., Prunotto, A., Andrieu-Soler, C., Rivolta, C., Canonica, J., Naud, M.C., Lechner, S., Farman, N., Bravo-Osuna, I., Herrero-Vanrell, R., Jaisser, F., Behar-Cohen, F., Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat. Commun., 10, 2019, 369.
101. Zhao, M., Valamanesh, F., Celerier, I., Savoldelli, M., Jonet, L., Jeanny, J.C., Jaisser, F., Farman, N., Behar-Cohen, F., The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 24 (2010), 3405–3415.
102. Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., Loibner, H., Wang, X.H., Penninger, J.M., Kassiri, Z., Oudit, G.Y., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728 718 pp. following 728.